<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043536</url>
  </required_header>
  <id_info>
    <org_study_id>0244-1blni08 / 009.020</org_study_id>
    <nct_id>NCT01043536</nct_id>
  </id_info>
  <brief_title>Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults</brief_title>
  <acronym>SIB-IMRT</acronym>
  <official_title>Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost in Association With a Temozolomide in the Treatment of Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to evaluate and to determine the dose of a highly accurate
      irradiation (allowing to increase the dose delivered while restricting the risk of
      complication) in association with temozolomide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the OTR (optimal tolerated regimen) of radiotherapy administered in combination with temozolomide as first-line therapy in patients with de novo glioblastoma</measure>
    <time_frame>3 months after the start of the radiotherapy</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>radiotherapy + temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy:
dose given at PTV-g will be 70 Gy/28 fractions level 1 75 Gy/30 fractions level 2 80 Gy/32 fractions level 3
dose given at PTV-a will be 56 Gy/28 fractions level 1 60 Gy/30 fractions level 2 60.8 Gy/32 fractions level 3
Chemotherapy:
temozolomide given at the dose of 75mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.</description>
    <arm_group_label>radiotherapy + temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.</description>
    <arm_group_label>radiotherapy + temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically proven diagnosis of glioblastoma (WHO grade IV astrocytoma)

          -  Diagnosis must be obtained by a stereotactic or surgical biopsy

          -  Age between 18 and 70

          -  Total or partial surgical resection deemed as not possible by a neurosurgeon

          -  OMS performance status 0 or 1

          -  Adequate blood function : absolute neutrophil count &gt; 1.5 x 109/L, platelets count &gt;
             100 x 109/L platelets;

          -  Adequate liver function: bilirubin &lt; 1.5 ULN (upper limit of normal), ALT and AST &lt; 3
             ULN,

          -  Adequate renal function: creatinine &lt; 1.5 ULN

          -  Patient must have been informed and must have signed the specific informed consent
             form.

        Exclusion Criteria:

          -  other malignancy histology

          -  resection of the brain tumor complete on MRI exploration

          -  patient unable to give informed consent

          -  patient presenting counter-indication to MRI exploration

          -  patient must not have received neither radiotherapy nor chemotherapy for that
             affection

          -  concomitant malignancy

          -  patient already enrolled in another biomedical study with an experimental molecule

          -  pregnant, nursing woman, or without contraception

          -  private individuals of freedom or under tutelage (including legal guardianship)

          -  psychiatric, behavioural disorders or geographical situation precluding the
             administration or follow-up of the protocol (including claustrophobia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Truc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Georges François Leclerc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <state>Bourgogne</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2010</study_first_posted>
  <last_update_submitted>September 24, 2012</last_update_submitted>
  <last_update_submitted_qc>September 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMRT</keyword>
  <keyword>Radiotherapy escalation dose</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>escalation radiotherapy dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

